Shenzhen YHLO Biotech Co Ltd
SSE:688575
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shenzhen YHLO Biotech Co Ltd
SSE:688575
|
8.2B CNY |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.5B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.9B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
137.1B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Shenzhen YHLO Biotech Co Ltd
Glance View
In the bustling city of Shenzhen, a beacon of China's rapid technological advancement, YHLO Biotech Co Ltd has emerged as a dynamic player in the healthcare diagnostics industry. Founded in 2008, YHLO Biotech focuses on the development, manufacturing, and distribution of in-vitro diagnostic products. By leveraging cutting-edge immunodiagnostic technologies, the company spearheads innovations in autoimmune disease diagnostics, infectious disease testing, and respiratory pathogen detection. Driven by a commitment to precision and reliability, YHLO Biotech integrates advanced automation solutions and robust biological research to produce diagnostic kits that serve hospitals, laboratories, and research institutions across the globe. YHLO Biotech's business model revolves around an intricate blend of product sales and strategic partnerships. By establishing a diverse portfolio of diagnostic instruments and reagent kits, they cater to both public and private healthcare sectors. The company also engages in collaborations with international diagnostic companies, enhancing its global footprint and broadening market access. Revenue generation at YHLO Biotech is primarily rooted in the sale of these diagnostic solutions, which are consistently updated to meet evolving medical standards and demands. Coupled with their investment in R&D and a rigorous quality control process, YHLO Biotech not only maintains a competitive edge but also fortifies its position as a trusted entity within the medical diagnostics landscape.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Shenzhen YHLO Biotech Co Ltd is 12.6%, which is below its 3-year median of 17.3%.
Over the last 3 years, Shenzhen YHLO Biotech Co Ltd’s Operating Margin has decreased from 27.6% to 12.6%. During this period, it reached a low of 11.8% on Mar 31, 2024 and a high of 29.4% on Sep 30, 2022.